Study the Usefulness of Bio-impedance Spectroscopy in the Early Assessment of Breast Cancer Related Lymphoedema
NCT ID: NCT01599039
Last Updated: 2016-09-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
80 participants
OBSERVATIONAL
2012-05-31
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lymphedema Screening
NCT04606511
Prospective Screening for Breast Cancer-related Lymphedema
NCT01521741
Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening
NCT03861975
Digital 3D Breast Tomosynthesis Versus 2D in Clinical Evaluation of High Risk Women
NCT02209129
Identification of a Screening Tool and Treatment of Lymphedema Secondary to the Management of Breast Cancer Study
NCT00282529
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Early detection with BIS is supposed possible even before clinical signs of swelling are available.
In this study we want to study this hypothesis and as control-group patients treated for colorectal carcinoma.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
breast cancer patients with SN
1\. Breast cancer patients with sentinel node biopsy (n=25)
No interventions assigned to this group
breast cancer patients with AD
2\. Breast cancer patients with axillary dissection (n=25)
No interventions assigned to this group
colo-rectal patients
3\. Colo-rectal patients as control group (n=25)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients operated with lumpectomy or mastectomy, Sentinel node, axillary lymphnode dissection and/or chemotherapy and/or radiotherapy.
* Controls: operated for colon-rectal carcinoma with colectomy and adjuvant chemotherapy
* Patients 18 years or older
* No pre-existing clinical or volumetric signs of lymphoedema (CBO guideline: \>10% difference with contra-lateral side
Exclusion Criteria
* Patients who have a pacemaker or other inbuilt stimulator
* Women who are pregnant
* Patients with renal failure or heart failure
* Lymphoedema
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nij Smellinghe Hosptial
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
R.J. Damstra
Dermatologist MD PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert J Damstra, PhD
Role: PRINCIPAL_INVESTIGATOR
Nij smellinghe hospital, Netherlands
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Expert Center for Lymphovascular Medicine Nij Smellinghe Hospital
Drachten, Provincie Friesland, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
The foundation related to the expert centre organizing research
General website form the Nij Smellinghe hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NS3NL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.